6940-81-4

Usage

Uses

Used in Pharmaceutical Synthesis:
2-Benzylamino-propan-1-ol is used as an intermediate in the synthesis of pharmaceuticals, contributing to the development of various medicinal compounds due to its unique chemical structure and reactivity.
Used in Organic Compounds Synthesis:
It serves as a key intermediate in the synthesis of organic compounds, facilitating the creation of a wide range of chemical products through its reactive functional groups.
Used in Surfactant Production:
2-Benzylamino-propan-1-ol is utilized in the production of surfactants, which are essential in various industries for their properties to reduce surface tension between liquids and solids, enhancing the effectiveness of cleaning and emulsifying processes.
Used in Detergent Manufacturing:
In the detergent industry, 2-Benzylamino-propan-1-ol is used to produce effective cleaning agents, taking advantage of its surfactant properties to improve the performance of detergent formulations.
Used in Other Industrial Applications:
Beyond its applications in pharmaceuticals, organic synthesis, surfactants, and detergents, 2-Benzylamino-propan-1-ol also finds use in other industrial applications, capitalizing on its versatile chemical properties for diverse purposes.

InChI:InChI=1/C10H15NO/c1-9(8-12)11-7-10-5-3-2-4-6-10/h2-6,9,11-12H,7-8H2,1H3

Upstream product

• 17966-60-8 D-N-benzoylalanine 
• 2198-64-3 N-benzoyl-L-alanine 
• 2749-11-3 (S)-Alaninol 
• 100-52-7 benzaldehyde 
• 56-41-7 L-alanin 
• 65943-49-9 (S)-2-{[1-Phenyl-meth-(E)-ylidene]-amino}-propan-1-ol 
• 3217-09-2 2-(benzylamino)-1-propanol 
• 697763-59-0 (R)-2-{[1-Phenyl-meth-(E)-ylidene]-amino}-propan-1-ol 
• 6168-72-5 2-Amino-1-propanol 
• 1252059-62-3 C₁₂H₁₅NO₂ 
• 100-39-0 benzyl bromide 
• 2198-64-3 N-Benzoylalanine 
• 98-88-4 benzoyl chloride 
• 35320-23-1 (R)-2-aminopropan-1-ol 

Downstream Products

• 74609-49-7 (2R)-2-[(phenylmethyl)amino]-1-propanol 
• 911792-37-5 4-benzyl-5-methylmorpholin-2-one 
• 120800-93-3 2-[Benzyl-(2-hydroxy-1-methyl-ethyl)-amino]-N-(1-phenyl-ethyl)-acetamide 
• 122764-74-3 6-methyl-9,10-didehydro-ergoline-8β-carboxylic acid-[benzyl-((S)-β-hydroxy-isopropyl)-amide] 
• 118460-11-0 (S)-4-benzyl-5-methylmorpholin-2-one 
• 172034-96-7 2-{[Benzyl-((S)-2-hydroxy-1-methyl-ethyl)-amino]-methyl}-acrylic acid ethyl ester 
• 148759-63-1 (S)-(+)-2-Allyl(benzyl)amino-1-propanol 

Relevant academic research and scientific papers

Anchored Palladium Complex-Generated Clusters on Zirconia: Efficiency in Reductive N-Alkylation of Amines with Carbonyl Compounds under Hydrogen Atmosphere

Carbon-nitrogen bond formation is an important method on both laboratory and industrial scales because it realizes the production of valuable pharmaceuticals, agrochemicals, and fine chemicals. Direct reductive N-alkylation of amines with carbonyl compounds via intermediary imine compounds, especially under catalytic hydrogenation conditions, is one of the most convenient, economical, and environmentally friendly methods for this process. Here we report a novel palladium species on zirconia having specific activity towards hydrogenation of imines but other carbonyl groups remaining intact. The present catalytic property offers a practical synthetic method of functionalized secondary amines by reductive N-alkylation under mild conditions with high atom-efficiency. Mechanistic studies revealed that the catalytically active species is the palladium cluster, which is generated in situ from molecular palladium complexes on the support by exposure to atmospheric hydrogen. These fundamental findings are expected to progress in developing novel cluster catalysts for chemical processes directed towards a sustainable society.

Microwave-Assisted CuCl-Catalyzed Three-Component Reactions of Alkynes, Aldehydes, and Amino Alcohols

A microwave (MW)-assisted three-component coupling of amino alcohols, aldehydes, and alkynes is developed under catalysis by CuCl. Compared with thermal conditions, MW irradiation greatly increases the reaction efficiency. The reactions of various primary N -alkyl/arylamino alcohols, aliphatic/aromatic aldehydes, and alkynes are systematically investigated, affording the desired products in moderate to good yields. Notably, acetylene is also an effective reactant under the current MW-assisted conditions.

6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE AND 6,7-DIHYDRO-4H-TRIAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES

The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R4 and Q are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.

CONJUGATES COMPRISING RIPK2 INHIBITORS

The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of RIP2 kinase, including degrading RIP2 kinase, the treatment of diseases and conditions mediated by the RIP2 kinase, in particular for the treatment of inflammatory diseases or conditions.

Substrate-Controlled Diastereoselectivity Reversal in NHC-Catalyzed Cross-Benzoin Reactions Using N-Boc-N-Bn-Protected α-Amino Aldehydes

The effectiveness of utilizing N-Bn-N-Boc-α-amino aldehydes in cross-benzoin reactions with heteroaromatic aldehydes is demonstrated. The reaction is both chemoselective and syn-selective, making it complementary to the anti-selective cross-benzoin reaction of NHBoc-α-amino aldehydes. Good diastereoselectivity is obtained for a variety of amino aldehydes, including nonhindered ones. A Felkin-Anh model can be used to rationalize the observed diastereoselectivity.

IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF

This invention generally relates to substituted imidazopyridine compounds, particularly substituted 4-(imidazo[1,2-a]pyridin-2-yl)benzamide compounds and salts thereof. This invention also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including, for example, treatment methods and medicament preparations), processes for making such a compound, and intermediates used in such processes.

Design, synthesis and crystal structure determination of dinuclear copper-based potential chemotherapeutic drug entities; In vitro DNA binding, cleavage studies and an evaluation of genotoxicity by micronucleus test and comet assay

Copper-based potential chemotherapeutic complexes 1 and 2 were designed, synthesized and evaluated for in vitro DNA binding, cleaving capability and in vivo genotoxicity. The structural elucidation of complexes was done using elemental and spectroscopic data while the (R)-enantiomer of Cu(ii) complex 1 was studied by single crystal diffraction. In vitro DNA binding profiling of both (R)- and (S)-enantiomers of complexes 1 and 2 was carried out to evaluate their enantioselectivity, exhibiting a remarkable degree of enantioselectivity in their interaction with DNA, with the (R)-enantiomer exhibiting greater DNA binding propensity. Interaction between complexes and pBR322 DNA was evaluated by agarose gel electrophoresis assay; both the (R)-enantiomeric complexes exhibit effective DNA cleavage and proceed via an oxidative pathway. Furthermore, the in vivo genotoxicity of the (R)-enantiomer of complex 1 was evaluated by micronucleus testing on bone marrow cells and comet assay in peripheral blood lymphocytes. These results support our contention that the (R)-enantiomer of complex 1 is a suitable chemotherapeutic drug candidate showing reduced toxic effects on normal cells as compared to cisplatin and an antioxidant (EVOO). The Royal Society of Chemistry.

A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to a novel compound, or a stereoisomer, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for human-11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) comprising the same. The invention provides a compound, which has excellent activity and solubility and is more efficiently formulated and delivered, and a pharmaceutical composition for human-11-beta-hydroxysteroid dehydrogenase type 1 comprising the same.

Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors

Phosphoinositide-dependent protein kinase-1(PDK1) is a master regulator of the AGC family of kinases and an integral component of the PI3K/AKT/mTOR pathway. As this pathway is among the most commonly deregulated across all cancers, a selective inhibitor of PDK1 might have utility as an anticancer agent. Herein we describe our lead optimization of compound 1 toward highly potent and selective PDK1 inhibitors via a structure-based design strategy. The most potent and selective inhibitors demonstrated submicromolar activity as measured by inhibition of phosphorylation of PDK1 substrates as well as antiproliferative activity against a subset of AML cell lines. In addition, reduction of phosphorylation of PDK1 substrates was demonstrated in vivo in mice bearing OCl-AML2 xenografts. These observations demonstrate the utility of these molecules as tools to further delineate the biology of PDK1 and the potential pharmacological uses of a PDK1 inhibitor.

NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF

A compound of the following general formula [I]: wherein each symbol has the same meaning as defined herein, or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutical use of the same in treating organ transplant rejection, graft versus host reaction after transplantation, autoimmune disease, allergic disease and chronic myeloproliferative disease.